<DOC>
	<DOCNO>NCT00635323</DOCNO>
	<brief_summary>To evaluate safety efficacy irinotecan capecitabine Asian subject inoperable hepatocellular carcinoma .</brief_summary>
	<brief_title>Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Asian subject histologically cytologically confirm hepatocellular carcinoma Inoperable disease ( unable completely remove surgically , presence extrahepatic disease , main portal vein hepatic vein involvement ) Eastern Cooperative Oncology Group performance status ? 2 Decompensated cirrhosis stage C ( Index &gt; 10 ) accord ChildPugh Classification Current history chronic diarrhoea Reproductive potential use adequate contraceptive measure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>